Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China.

IF 3.4 2区 医学 Q2 ONCOLOGY
Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Lin-Xiaoxi Ma, Haoqi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xu Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu
{"title":"Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China.","authors":"Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Lin-Xiaoxi Ma, Haoqi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xu Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu","doi":"10.1186/s12885-025-14223-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To investigate the treatment pattern, adverse events, and quality of life of Chinese patients treated with CDK4/6 inhibitors (CDK4/6i) for hormone receptor (HR)+/HER2- advanced breast cancer.</p><p><strong>Methods: </strong>This multicenter cross-sectional survey enrolled patients with HR+/HER2- advanced breast cancer currently treated with CDK4/6i. The patients reported adverse events and quality of life during CDK4/6i treatment with a questionnaire and EORTC QLQ-BR23. Meanwhile, the oncologists collected the treatment information, adverse events and patient characteristics from medical record.</p><p><strong>Results: </strong>The analysis included 1254 patients. Most patients received only one CDK4/6i, of which 38.92% received dalpiciclib, 35.81% received abemaciclib, 15.07% received palbociclib, and 0.47% received ribociclib, while 9.73% patients were treated with two CDK4/6i sequentially. The oncologists reported adverse events occurred in > 81.17% of patients, and most common AEs were leukopenia (63.30%) and neutropenia (58.73%). The most common symptomatic adverse events reported by the patients were fatigue (34.13%), alopecia (14.02%) and weakness (11.30%). The incidence of alopecia in patients receiving dalpiciclib was lower than in those receiving palbociclib (8.81% vs. 16.40%, P < 0.001) and abemaciclib (8.81% vs. 19.82%, P = 0.027). Regard to quality of life, breast symptom scores were lower in the palbociclib group than in the abemaciclib group (3.84 ± 8.57 vs. 5.70 ± 9.81, P = 0.047). Patient reported alopecia was associated with body image, systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss (all P < 0.001).</p><p><strong>Conclusions: </strong>The safety profile of different CDK4/6i varies and has different impacts on patients' quality of life, which needs more attention in clinical practice.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"951"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117832/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14223-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To investigate the treatment pattern, adverse events, and quality of life of Chinese patients treated with CDK4/6 inhibitors (CDK4/6i) for hormone receptor (HR)+/HER2- advanced breast cancer.

Methods: This multicenter cross-sectional survey enrolled patients with HR+/HER2- advanced breast cancer currently treated with CDK4/6i. The patients reported adverse events and quality of life during CDK4/6i treatment with a questionnaire and EORTC QLQ-BR23. Meanwhile, the oncologists collected the treatment information, adverse events and patient characteristics from medical record.

Results: The analysis included 1254 patients. Most patients received only one CDK4/6i, of which 38.92% received dalpiciclib, 35.81% received abemaciclib, 15.07% received palbociclib, and 0.47% received ribociclib, while 9.73% patients were treated with two CDK4/6i sequentially. The oncologists reported adverse events occurred in > 81.17% of patients, and most common AEs were leukopenia (63.30%) and neutropenia (58.73%). The most common symptomatic adverse events reported by the patients were fatigue (34.13%), alopecia (14.02%) and weakness (11.30%). The incidence of alopecia in patients receiving dalpiciclib was lower than in those receiving palbociclib (8.81% vs. 16.40%, P < 0.001) and abemaciclib (8.81% vs. 19.82%, P = 0.027). Regard to quality of life, breast symptom scores were lower in the palbociclib group than in the abemaciclib group (3.84 ± 8.57 vs. 5.70 ± 9.81, P = 0.047). Patient reported alopecia was associated with body image, systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss (all P < 0.001).

Conclusions: The safety profile of different CDK4/6i varies and has different impacts on patients' quality of life, which needs more attention in clinical practice.

CDK4/6抑制剂治疗激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌的安全性和生活质量:中国一项多中心横断面调查
背景:探讨CDK4/6抑制剂(CDK4/6i)治疗激素受体(HR)+/HER2-晚期乳腺癌患者的治疗模式、不良事件和生活质量。方法:这项多中心横断面调查纳入了目前接受CDK4/6i治疗的HR+/HER2晚期乳腺癌患者。患者通过问卷调查和EORTC QLQ-BR23报告CDK4/6i治疗期间的不良事件和生活质量。同时,肿瘤学家从病历中收集治疗信息、不良事件和患者特征。结果:共纳入1254例患者。大多数患者只接受了一种CDK4/6i治疗,其中38.92%的患者接受了达匹昔利,35.81%的患者接受了阿贝马昔利,15.07%的患者接受了帕博西尼,0.47%的患者接受了核糖西尼,而9.73%的患者连续接受了两种CDK4/6i治疗。肿瘤学家报告的不良事件发生率为81.17%,最常见的不良事件为白细胞减少(63.30%)和中性粒细胞减少(58.73%)。患者最常见的不良反应是疲劳(34.13%)、脱发(14.02%)和虚弱(11.30%)。结论:不同CDK4/6i的安全性存在差异,对患者的生活质量有不同的影响,在临床实践中需要引起更多的重视。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Cancer
BMC Cancer 医学-肿瘤学
CiteScore
6.00
自引率
2.60%
发文量
1204
审稿时长
6.8 months
期刊介绍: BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信